Cargando…
Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease
Alzheimer's disease (AD) and Parkinson's disease (PD) are the first and second most common neurodegenerative disorders, respectively. Both are proteinopathies with inexorable courses and no approved disease-modifying therapies. A substantial effort has been made to identify interventions t...
Autor principal: | de Aquino, Camila Henriques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377160/ https://www.ncbi.nlm.nih.gov/pubmed/34421799 http://dx.doi.org/10.3389/fneur.2021.694329 |
Ejemplares similares
-
Clinical and Imaging Markers of Prodromal Parkinson's Disease
por: Hustad, Eldbjørg, et al.
Publicado: (2020) -
Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021) -
Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease
por: De Groote, Evelien, et al.
Publicado: (2020) -
Prodromal Markers of Parkinson's Disease in Patients With Essential Tremor
por: Wang, Xi-Xi, et al.
Publicado: (2020) -
Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective
por: Vermeiren, Yannick, et al.
Publicado: (2020)